Given that LGG treatment induced an increased expression of MOR in the DH, we continued to test whether LGG supplementation could facilitate the analgesic effect of morphine, which is an agonist of MOR and a drug used widely in patients bearing with cancer pain. The gene discussed is OPRM1; the disease is cancer.